HighTower Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

HighTower Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-700	Closed	-$1K	–	2178
2017 Q4	$1K	Buy	+700	New	+$22.4K	﹤0.01%	2248
2017 Q2	–	Sell	-800	Closed	-$5K	–	2212
2017 Q1	$5K	Sell	800 -300	-27%	-$10.6K	﹤0.01%	2034
2016 Q4	$1K	Buy	+1,100	New	+$29.1K	﹤0.01%	1911
2016 Q2	–	Sell	-1,500	Closed	-$225K	–	1761
2016 Q1	$225K	Buy	+1,500	New	+$32.7K	﹤0.01%	1758

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

HighTower Advisors's ACAD Position: Q1 2026 in Review

HighTower Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 9,965 shares — an estimated $266K sold.

HighTower Advisors first reported a position in ACAD in Q1 2015 and held it in 18 quarters. The position peaked at $1.08M in Q1 2022. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

HighTower Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
HighTower Advisors sold 9,965 Acadia Pharmaceuticals shares in Q1 2026, an estimated $266K.
HighTower Advisors first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 18 quarters.
HighTower Advisors's Acadia Pharmaceuticals position peaked at $1.08M in Q1 2022.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.